Nanobiotix SA (NBTX) Stock Price, Financials & Summary

Price chart

Sep 8Sep 11Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7

Key dataOct 7, 2026

Open$24.68

From 52W high−55.29%

Volume142605.00

Market cap$1.25B

P/E (TTM)—

P/S (TTM)130.1x

Div yield—

Key dataOct 7, 2026

Open

$24.68

From 52W high

−55.29%

Volume

142605.00

Market cap

$1.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−34.2x

P/E (TTM)

—

RSI (14)

24.1

MomentumView details →

1D Return

−2.42%

YTD Return

+7.31%

SummaryUpdated Jun 1, 2026

Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.

Ask drillr about Nanobiotix SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−34.2x

EV/Sales

129.6x

P/S (TTM)

130.1x

P/B (TTM)

−33.4x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−623.28%

EBITDA Margin

−379.36%

ROE (TTM)

159.82%

ROA (TTM)

−41.57%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

−15.78%

EPS YoY

−0.92%

FCF YoY

−24.46%

Revenue CAGR 3Y

+83.77%

EPS CAGR 3Y

+65.28%

EBITDA YoY

+25.09%

MomentumView details →

1D Return

−2.42%

YTD Return

+7.31%

1Y Return

−9.12%

RSI (14)

24.1

vs 50D SMA

−32.91%

vs 200D SMA

−25.80%

Capital & dividendView details →

Debt/Equity

−3.19x

Current Ratio

1.44x

Quick Ratio

1.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.80

EPS Surprise

−64.70%

Beats (12Q)

3/12

Next Q EPS Est

—

Avg Surprise (4Q)

−83.25%

Rev Surprise

268.93%

Financials snapshotView financials →

Revenue (TTM)

18.71M

Net Income (TTM)

−104.97M

Op. CF (TTM)

−69.46M

Next earningsApr 27, 2027 →

Latest newsMore news →

Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.6d ago

Nanobiotix reported its operational progress and financial results for the first half of 2026.13d ago

Similar companies

Damora Therapeutics, Inc.DMRA ST嘉必优688089.SH ORIC Pharmaceuticals, Inc.ORIC Replimune Group, Inc.REPL Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK JW (Cayman) Therapeutics Co. Ltd02126.HK Find similar companies →

Latest newsMore news →

Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.6d ago Nanobiotix reported its operational progress and financial results for the first half of 2026.13d ago